Grand Rapids’ BAMF Health is offering Alzheimer’s Disease treatment to anyone with early warning signs of the disease.
“Recently some new monoclonal antibody treatments for Alzheimer’s were approved by the FDA.”
It’s welcome news for Michigan’s 190,000 residents diagnosed with Alzheimer’s.
Dr. Jeremiah Johns is Vice-President of Medical Affairs at BAMF. He says health systems are ramping up their ability providing these new treatments.
“BAMF Health is well-positioned to be a one-stop shop for diagnosing Alzheimer’s and treating it because of the colocation of our advanced PET scanners.”
Treatment involves injecting antibodies into the bloodstream. Those antibodies travel to the patient’s brain and remove amyloid plaques which are believed to contribute to dementia caused by Alzheimer’s Disease.
Dr. Johns says BAMF Health patients in the early stages of the disease can receive tests and scans.
“We can do the amyloid PET scan and the MRI all in one test, which can save them from having to go get two tests because at another place, they’d have to go get an amyloid PET CT scan and a separate MRI of the brain.”
More information can be found online at BAMFhealth.com
